Moreover, the integration of PSMA-PET imaging into clinical guidelines as a first-line imaging option for primary staging of prostate cancer reflects its growing importance in the personalized management of prostate cancer [7]. This evidence concerns the gene FOLH1 and prostate carcinoma.